Curis Inc (CRIS) Q3 2025 Earnings Call Highlights

 

Positive Points

• Curis Inc (NASDAQ:CRIS) is making steady progress in their Take Aim Lymphoma study, which could support accelerated submissions in the US and Europe.

• The company is exploring the potential of emusertib to change the treatment paradigm for CLL patients, aiming for deeper responses and improved quality of life.

• Initial data from the AML triplet study shows promising MRD conversion rates, with no disease progression observed among patients.

• Curis Inc (NASDAQ:CRIS) reported a reduced net loss for Q3 2025 compared to the same period in 2024, indicating improved financial management.

• The company has sufficient cash and cash equivalents to fund operations into 2026, providing a stable financial outlook.

Negative Points

• Curis Inc (NASDAQ:CRIS) continues to operate at a net loss, with $7.7 million reported for Q3 2025.

• Research and development expenses, although reduced, still represent a significant cost, impacting overall financial performance.

• The company anticipates the need to raise additional capital before the end of the year, indicating potential financial constraints.

• There are dose-limiting toxicities observed in the AML triplet study, which could impact the study's progression and outcomes.

• The success of ongoing studies is contingent on regulatory approvals and successful patient enrollment, which carry inherent risks and uncertainties.

Q: Can you provide details on the FDA discussions and the protocol submitted for the CLL program? A: (Jim Denser, CEO) We are excited about the CLL study, which addresses unmet medical needs by combining emusertib with a BTK inhibitor for patients who have only achieved a partial response. (Dr. Ahmed Hamdi, Chief Medical Officer) We are aligned with the FDA and plan a dose escalation study starting at 100 mg, expanding to 200 mg in phase two.

Q: Could you discuss the size of the phase two CLL trial and resource prioritization? A: (Jim Denser, CEO) The CLL study is designed for 40 patients, aiming to demonstrate deeper responses by blocking both pathways driving the disease. (Dr. Ahmed Hamdi, Chief Medical Officer) Achieving a complete response rate above 20% would be exciting. (Diana Duval, CFO) Our priorities include continuing the PCNSL trial and launching the CLL trial, with plans to secure additional capital by year-end.

Q: What are the safety considerations for the CLL study, particularly regarding potential adverse events? A: (Jim Denser, CEO) We are monitoring for any drug-drug interactions with BTK inhibitors. (Dr. Ahmed Hamdi, Chief Medical Officer) We have tested emusertib with ibrutinib in NHL patients without seeing additive toxicities, and we expect similar results with other BTK inhibitors.

Q: What should investors expect from the upcoming Snow conference? A: (Jim Denser, CEO) We will present several posters, including updates on PCNSL and secondary CNS lymphoma studies. Expect to learn more about our progress over the last six months and new findings in secondary CNS lymphoma.

Q: How is Curis managing its financial resources given the ongoing trials? A: (Diana Duval, CFO) We are focused on continuing our PCNSL and CLL trials and plan to raise additional capital before the end of the year to support these initiatives.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

https://finance.yahoo.com/news/curis-inc-cris-q3-2025-050229378.html